FDA Approves Epysqli (eculizumab-aagh), a Biosimilar to Soliris

FDA approves Epysqli (eculizumab-aagh), a biosimilar to Soliris for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), based on evidence showing high similarity to Soliris without clinically meaningful differences in safety, purity, and potency.